A research team from Memorial Sloan-Kettering Cancer Center in New York City identified cells in brain tumors called glioblastomas that have stem-cell like properties and help cancer cells survive chemotherapy. The surviving cells become resistant to the drug most commonly used to treat this type of brain cancer - Temozolomide, known by it’s brand name Temodar.
Glioblastomas have an almost 100% recurrence rate, and conventional medicine has no answer as to why. This new study may shed light on one of the causes, but offers no options for treatment or alternatives.
Dr. Ronald Benveniste is an assistant professor of neurosurgery at the University of Miami School of Medicine. He explains that mice treated with Temodar tend to have a recurrence of the glioblastomas, and the recurring tumors act more aggressive and have developed resistance to the drug.
You can read the original article here: Brain Tumor Drug May Help Spur Cancer’s Return
The unique, proprietary formula used by Camelot Cancer Care to combat gliomas and other brain tumors offers patients a non-toxic, natural treatment that has proven effective in many patients and without the brutal side effects of conventional chemotherapy.